北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第一临床医学院  > 期刊论文
学科主题: 临床医学
题名:
Augmented antitumor effects of combination therapy of cisplatin with ethaselen as a novel thioredoxin reductase inhibitor on human A549 cell in vivo
作者: Tan, Qiang1,2; Li, Jing2; Yin, Han-wei3; Wang, Li-hui2; Tang, Wan-chen2; Zhao, Fang2; Liu, Xin-min1; Zeng, Hui-hui2,4
关键词: Ethaselen ; Thioredoxin reductase inhibitor ; Cisplatin ; Non-small cell lung cancer ; Combination chemotherapy ; Synergistic effect
刊名: INVESTIGATIONAL NEW DRUGS
发表日期: 2010-06-01
DOI: 10.1007/s10637-009-9235-7
卷: 28, 期:3, 页:205-215
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Oncology ; Pharmacology & Pharmacy
研究领域[WOS]: Oncology ; Pharmacology & Pharmacy
关键词[WOS]: LUNG-CANCER CELLS ; MAMMALIAN THIOREDOXIN ; POSSIBLE INVOLVEMENT ; CYCLE ARREST ; APOPTOSIS ; CARCINOMA ; DESIGN ; GROWTH ; LINES ; CIS-DIAMMINEDICHLOROPLATINUM(II)
英文摘要:

Ethaselen (1, 2-[bis (1, 2-Benzisoselenazolone-3 (2H) -ketone)] ethane, BBSKE), as a novel organoselenium compound targeting thioredoxin reductase (TrxR), has been reported to inhibit tumor growth and TrxR activity in several human tumor cell lines. It has now entered Phase I clinical trails. Here we report the effects of ethaselen and cisplatin (cis-diamminedichloroplatinum II, DDP) combination therapy (ethaselen 36 mg/kg, i.g., o.d. x 10 d and cisplatin 1 mg/kg, i.p., single at day 0) on human A549-grafted nude mouse model (female, BALB/c nude mouse, n = 5, treatment after tumor volume reached 100 mm(3)). Compared to single drug administration (either ethaselen: 36 mg/kg, i.g., o.d. x 10 d or cisplatin: 1.0 mg/kg, i.p., single at day 0), the combination therapy showed significantly reduced tumor size (presumably due to a synergistic effect) and no obvious toxic damage (both in terms of body weight maintenance and liver/kidney damage). These results will be significant in the development of novel anti-tumoral therapeutic strategies directed to non-small cell lung cancer (NSCLC).

语种: 英语
所属项目编号: 30472036
项目资助者: National Natural Science Foundation of China
WOS记录号: WOS:000276430200001
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/50438
Appears in Collections:北京大学第一临床医学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Hosp 1, Beijing 100034, Peoples R China
2.Peking Univ, Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, Beijing 100191, Peoples R China
3.Peking Univ, Coll Life Sci, Beijing 100075, Peoples R China
4.Peking Univ, Hlth Sci Ctr, Sch Pharmaceut Sci, Beijing 100191, Peoples R China

Recommended Citation:
Tan, Qiang,Li, Jing,Yin, Han-wei,et al. Augmented antitumor effects of combination therapy of cisplatin with ethaselen as a novel thioredoxin reductase inhibitor on human A549 cell in vivo[J]. INVESTIGATIONAL NEW DRUGS,2010,28(3):205-215.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Tan, Qiang]'s Articles
[Li, Jing]'s Articles
[Yin, Han-wei]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Tan, Qiang]‘s Articles
[Li, Jing]‘s Articles
[Yin, Han-wei]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace